Morristown-based Alitair Pharmaceuticals announced Wednesday its licensing agreement with Italian company Edmond Pharma regarding the latter's mucolytic erdosteine. Financial terms of the agreement were not disclosed.
According to the announcement, erdosteine is a mucolytic with antibacterial, anti-inflammatory and antioxidant properties. The agreement allows for Alitair's development of erdosteine as an orphan drug in the United States and Canada.
Please note: All comments will be reviewed and may take up to 24 hours to appear on the site.View Comment Policy